ResearcherKaohsiung Medical UniversityActive in the last 2 years
Mei‐Ren Pan
Matched on ORCID iD 0000-0003-2039-7570; OpenAlex author ID A5087856776. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 8
2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 7
- Exploring the characteristics of the SKP2-CDK6 axis in pancreatic cancer cell metastasis and its clinical significance. Last author DOI 10.1016/j.yexmp.2026.105024↗
- Clustering of Chromatin Remodeling Enzymes Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Pancreatic Cancer. Last author DOI 10.7150/ijms.73800↗
- Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer. Co-author DOI 10.1186/s13045-019-0769-7↗
- Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Last author DOI 10.3390/jcm8060903↗
- Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression. First author DOI 10.3390/cancers11010008↗
- Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. Last author PMID 30323973↗
- The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.11256↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Li‐Tzong Chen · 6 shared papers, 2016–2026 · strength 0.78
- Paper Exploring the characteristics of the SKP2-CDK6 axis in pancreatic cancer cell metastasis and its clinical significance. DOI 10.1016/j.yexmp.2026.105024↗
- Paper Clustering of Chromatin Remodeling Enzymes Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Pancreati… DOI 10.7150/ijms.73800↗
- Paper Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. DOI 10.3390/jcm8060903↗
- Hui‐Ching Wang · 3 shared papers, 2018–2026 · strength 0.48
- Paper Exploring the characteristics of the SKP2-CDK6 axis in pancreatic cancer cell metastasis and its clinical significance. DOI 10.1016/j.yexmp.2026.105024↗
- Paper Clustering of Chromatin Remodeling Enzymes Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Pancreati… DOI 10.7150/ijms.73800↗
- Paper Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cance… PMID 30323973↗
- Wen‐Chun Hung · 5 shared papers, 2016–2019 · strength 0.46
- Paper Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. DOI 10.3390/jcm8060903↗
- Paper Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer. DOI 10.1186/s13045-019-0769-7↗
- Paper Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase A… DOI 10.3390/cancers11010008↗
- Ming‐Chuan Hsu · 4 shared papers, 2016–2019 · strength 0.38
- Paper Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. DOI 10.3390/jcm8060903↗
- Paper Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer. DOI 10.1186/s13045-019-0769-7↗
- Paper Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase A… DOI 10.3390/cancers11010008↗
- Yan‐Shen Shan · 3 shared papers, 2016–2019 · strength 0.25
- Paper Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer. DOI 10.1186/s13045-019-0769-7↗
- Paper Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase A… DOI 10.3390/cancers11010008↗
- Paper The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. DOI 10.18632/oncotarget.11256↗
- Yung‐Yeh Su · 1 shared paper, 2022 · strength 0.14
- Yu‐Hsuan Hung · 1 shared paper, 2019 · strength 0.12
- Yufeng Tian · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.